Please Wait
Applying Filters...
Menu
Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 3Bonoteo

02 3Recalbon

PharmaCompass

01

Brand Name : Bonoteo

Minodronic Acid

arrow
Antibody Engineering
Not Confirmed

Brand Name : Bonoteo

arrow
Antibody Engineering
Not Confirmed

Minodronic Acid

Main Therapeutic Indication : Musculoskeletal

Currency : USD

2020 Revenue in Millions : 38

2019 Revenue in Millions : 59

Growth (%) : -36

blank

02

Brand Name : Recalbon

Minodronic Acid

arrow
Antibody Engineering
Not Confirmed

Brand Name : Recalbon

arrow
Antibody Engineering
Not Confirmed

Minodronic Acid

Main Therapeutic Indication : Musculoskeletal

Currency : USD

2020 Revenue in Millions : 30

2019 Revenue in Millions : 48

Growth (%) : -37

blank

03

Brand Name : Bonoteo

Minodronic Acid

arrow
Antibody Engineering
Not Confirmed

Brand Name : Bonoteo

arrow
Antibody Engineering
Not Confirmed

Minodronic Acid

Main Therapeutic Indication : Bone And Joint Diseases

Currency : USD

2018 Revenue in Millions : 90

2017 Revenue in Millions : 122

Growth (%) : -26%

blank

04

Brand Name : Bonoteo

Minodronic Acid

arrow
Antibody Engineering
Not Confirmed

Brand Name : Bonoteo

arrow
Antibody Engineering
Not Confirmed

Minodronic Acid

Main Therapeutic Indication : Musculoskeletal

Currency : USD

2019 Revenue in Millions : 60

2018 Revenue in Millions : 96

Growth (%) : -38

blank

05

Brand Name : Recalbon

Minodronic Acid

arrow
Antibody Engineering
Not Confirmed

Brand Name : Recalbon

arrow
Antibody Engineering
Not Confirmed

Minodronic Acid

Main Therapeutic Indication : Bone And Joint Diseases

Currency : USD

2018 Revenue in Millions : 77

2017 Revenue in Millions : 100

Growth (%) : -23%

blank

06

Brand Name : Recalbon

Minodronic Acid

arrow
Antibody Engineering
Not Confirmed

Brand Name : Recalbon

arrow
Antibody Engineering
Not Confirmed

Minodronic Acid

Main Therapeutic Indication : Musculoskeletal

Currency : USD

2019 Revenue in Millions : 47

2018 Revenue in Millions : 68

Growth (%) : -30

blank